Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication

Table 1 Baseline demographic and clinical characteristics (n = 992) n (%)

Variable	Information
Age (mean age ± SD)	46.7 ± 12.4
Gender
Male	501 (50.5)
Female	491 (49.5)
Smoking history	199/859 (23.2)
Alcohol intake history	231/859 (26.9)
Educational level
< 7 yr	164 (16.5)
7-9 yr	249 (25.1)
10-12 yr	197 (19.9)
13-16 yr	229 (23.1)
> 16 yr	20 (2.0)
Unknown	133 (13.4)
Diagnosis
Functional dyspepsia	478 (48.2)
Peptic ulcers	259 (26.1)
Erosive esophagitis	69 (7.0)
Other sources of upper GI bleeding	5 (0.5)
Gastric tumors	6 (0.6)
Asymptomatic gastritis	75 (7.6)
13C-UBT positive during health checkup	100 (10.1)
Number of previous H. pylori treatment(s)
None	842 (84.9)
One	127 (12.8)
Two or more	23 (2.3)
PPI type
Esomeprazole	264 (26.6)
Rabeprazole	224 (22.6)
Pantoprazole	435 (43.9)
Other PPIs	69 (7.0)
Bismuth dose
400 mg per day	213 (21.5)
600 mg per day	391 (39.4)
800 mg per day	388 (39.1)
Duration of regimen
14-d regimen	971 (97.9)
10-d regimen	21 (2.1)

GI: Gastrointestinal; PPI: Proton pump inhibitor;

¹³C-UBT: ¹³C-urea breath test.